A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
- 31 December 2011
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 123 (3), 486-491
- https://doi.org/10.1016/j.ygyno.2011.08.032
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late RelapseJournal of Clinical Oncology, 2010
- Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecologic Oncology, 2004
- Use of CA-125 to Assess Response to New Agents in Ovarian Cancer TrialsJournal of Clinical Oncology, 2003
- BRCA-related ovarian carcinomaCancer, 2003
- Improved survival in women with BRCA‐associated ovarian carcinomaCancer, 2003
- Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian CancerAmerican Journal of Human Genetics, 2001
- Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the PeritoneumGynecologic Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.1999
- Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological reviewBiochimie, 1984